Shidlovski/iStock via Getty Images
Cytokinetics (NASDAQ:CYTK) said EU regulators have validated the market application for its drug aficamten for the treatment of obstructive hypertrophic cardiomyopathy.
The application will next be reviewed by the European Medicines Agency’s Committee for Medicinal Products for Human Use.
